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 Abstract  In liver transplantation, prolonged ischemia and/or a relatively small 
graft (living, split, reduced) are the risk factors for liver dysfunction. Novel mea-
sures to enhance liver function with a smaller graft can be a clue for safe partial or 
living-donor liver transplantation or safe hepatectomy for malignant disease. The 
therapeutic potential and immunomodulatory effects of mesenchymal stem cells 
(MSCs) have been reported. In this chapter, recent ﬁ nding on the positive effect of 
MSCs for liver transplantation and hepatectomy are discussed. 
 Our rat experiment revealed that introduction of MSCs provides trophic support 
to the I/R-injured liver by inhibiting hepatocellular apoptosis and by stimulating 
regeneration, which is shown with the pig model as well. In the rat liver transplanta-
tion model, portal transfusion of the MSCs ameliorates the injury of the liver graft 
after prolonged cold preservation and transplantation. Those ﬁ ndings together sug-
gest a potential advantage with partial or living-donor liver transplantation. The 
most severe complication with cell therapy is embolus formation due to cell aggre-
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gation. However, with modiﬁ cation of the solution, we can keep cells in a sus-
pended form for several hours, which secures safe administration of MSCs. 
 Keywords  Liver transplantation •  Mesenchymal stem cell •  Hepatectomy • 
 Ischemia •  Reperfusion •  Liver failure •  Living donor •  Partial liver transplantation 
 Clinical Liver Transplantation: Deceased Donor vs. 
Living Donor 
 Statistics 
 Liver transplantation has been successfully used as a treatment for end-stage liver 
disease, though there has been discussion regarding where the liver graft is obtained, 
i.e., from a deceased donor or a living donor. In the USA, the majority of liver 
transplantation is done with deceased donors, and the number of living-donor liver 
transplantations (LDLTs) is limited. The reason why LDLT is not popular in the 
USA is due to the death of a donor in 2002. Since 2001, the number of patients who 
have undergone LDLT has declined. On the other hand, in Japan, most liver trans-
plantation is done with LDLT. Though the organ transplantation law took effect in 
1997, the number of deceased donor liver transplantations (DDLTs) has been mini-
mal; this is partly because the law itself is very strict in comparison with those of 
Western countries. Even since modiﬁ cation of the law in 2010, the annual number 
of DDLTs has been limited to below 50. The ratio of the numbers of LDLTs to 
DDLTs is 10:1 [ 1 ]. 
 Operations and the Post-transplant Course 
 In DDLT, the whole liver is used, and it has a high reserve capacity (Fig.  1 ). In other 
words, the liver volume is sufﬁ cient for the recipient throughout the postoperative 
course from the immediate post-transplant period. That is true with LDLT as well; 
therefore, a larger graft is preferable in terms of the recipient’s postoperative course. 
However, harvesting a larger graft from a living donor may cause complications, 
and there have been some reports of donor deaths. Currently, we primarily use 
smaller grafts such as left lobe grafts, in our program, though small-for-size 
 syndrome (SFSS) occasionally follows in recipients, which can be lethal. Since 
LDLT is a type of partial liver transplantation (PLTx), the possibility of SFSS is 
unavoidable. Functional impairment conditions such as prolonged cholestasis, asci-
tes, coagulopathy, and encephalopathy are considered to result from SFSS that 
occurs after LDLT [ 2 ]. They strongly affect patient survival and clinical costs for the 
whole treatment. Therefore, novel measures to enhance liver function with smaller 
grafts may be the key to safe PLTx or LDLT.
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 Mesenchymal Stem Cells 
 Characteristics 
 Mesenchymal stem cells (MSCs), present in the human body in large amounts, can 
be candidates for stem cell–based therapy for liver diseases. Recently, the therapeu-
tic potential and immunomodulatory effect of MSCs have been revealed. Adipose 
tissue–derived mesenchymal stem cells (AT-MSCs), because of their high accessi-
bility with minimal invasiveness, are especially attractive in the context of future 
clinical applications. MSCs can differentiate into multiple types of lineages, such as 
chondrogenic, osteogenic, and adipogenic, depending on the microenvironment 
around them. Importantly, human MSCs represent an advantageous cell type for 
allogeneic transplantation, as they are immunoprivileged with low human leukocyte 
antigen (HLA) I and no HLA II expression, thereby reducing the risk of allogeneic 
transplant rejection and preventing graft-versus-host disease (GVHD). According 
to Banas et al., adipose tissue–derived (AT) MSCs can improve liver functions, 
which we have veriﬁ ed by changes in the levels of biochemical parameters. 
Ammonia, uric acid, glutamic–pyruvic transaminase, and glutamic–oxaloacetic 
transaminase concentrations returned to a nearly normal level after AT-MSC trans-
plantation. It was shown that AT-MSCs secrete interleukin 1 receptor (IL-1R), IL-6, 




































 Fig. 1  Postoperative course of whole vs. partial liver transplantation, showing the difference 
between DDLT and LDLT after the operation. There is no change in size with DDLT, whereas graft 
enlargement is observed with LDLT. Functional recovery follows volume recovery; therefore, 
there should be some critical period with LDLT after operation 
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IL-8, granulocyte colony–stimulating factor (G-CSF), granulocyte-macrophage 
colony–stimulating factor (GM-CSF), monocyte chemotactic protein 1, nerve 
growth factor, and hepatocyte growth factor, suggesting that AT-MSCs account for 
broad therapeutic efﬁ cacy in animal models of liver diseases and in the clinical 
 settings of liver disease treatment [ 3 ]. 
 Isolation Techniques 
 AT-MSCs can be derived from subcutaneous adipose tissue. Adipose tissue was 
minced with scissors and scalpels into less than 3 mm pieces and, after gentle shak-
ing with an equal volume of PBS(−), the mixture was separated into two phases. 
The upper phase (containing stem cells, adipocytes, and blood), after washing with 
phosphate-buffered saline (PBS) (−), was enzymatically dissociated with 0.075 % 
collagenase (type I)/PBS(−) for 1 h at 37 °C with gentle shaking. The dissociated 
tissue was then mixed with an equal volume of DMEM, supplemented with 10 % 
fetal bovine serum (FBS) and incubated for 10 min at room temperature. The solution 
was then separated into two phases. The lower phase was centrifuged at 1500 rpm 
for 5 min at 20 °C. The cellular pellet was resuspended in 160 mM NH 4 Cl to elimi-
nate erythrocytes and passed through a 40 μm mesh ﬁ lter into a new tube. The cells 
were resuspended in an equal volume of DMEM/10 % FBS and then centrifuged. 
Isolation resulted in obtaining 7.7 × 10 6 of adherent cells for a primary culture from 
5 g of adipose tissue (approximately 1.0 × 10 5 to 4.6 × 10 6 /1 g) after 7–10 days of 
culture. The cells were suspended in DMEM/10 % FBS plated in a concentration of 
1–5 × 10 6 cells/75 cm 2 . The cells with 70–80 % conﬂ uence were harvested with 
0.25 % trypsin EDTA and then re-plated at 1.0 × 10 5 cells/60 mm dish and used for 
analysis [ 4 ]. 
 Mesenchymal Stem Cells for Rat Hepatectomy 
 Rat Hepatectomy Model 
 Our rat model provided the ideal animal model to research I/R injury after major 
hepatectomy by the Pringle maneuver or liver transplantation with small-for-size 
grafts (Fig.  2 ) [ 5 ]. Intestinal congestion was avoided during the application of 
hepatic ischemia by bypassing portal ﬂ ow through nonischemic lobes (the right and 
caudate lobes). Moreover, the left lateral and the left portion of the medial lobes, as 
well as the nonischemic lobes, were excised at the onset of reﬂ ow to mimic the 
clinical condition of liver transplantation with small-for-size grafts or major hepa-
tectomy by the Pringle maneuver in order to research postischemic liver functions.
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 Outcome After MSC Injection 
 Male Lewis rats were separated into two groups: an MSC group given MSCs after 
reperfusion as a treatment, and a control group given phosphate-buffered saline 
after reperfusion as a placebo. The results of liver function tests, pathologic changes 
in the liver, and the remnant liver regeneration rate were assessed. The fate of trans-
planted MSCs in the luciferase-expressing rats was examined by in vivo lumines-
cent imaging. The MSC group showed peak luciferase activity of transplanted 
MSCs in the remnant liver 24 h after reperfusion, after which luciferase activity 
gradually declined. The elevation of serum alanine transaminase levels was signiﬁ -
cantly reduced by the MSC injection. Histopathological ﬁ ndings showed that the 
vacuolar change was lesser in the MSC group than in the control group. In addition, 
a signiﬁ cantly lower percentage of TUNEL-positive cells was observed in the MSC 
group than in the controls. The remnant liver regeneration rate was accelerated in 
the MSC group. The above results suggest that MSC transplantation provides tro-
phic support to the I/R-injured liver by inhibiting hepatocellular apoptosis and by 
stimulating regeneration. 
Hepatectomy (70%) with I/R injury model (rat)
Lewis-rats, male
Warm ischemic time :40 min
Hepatectomy 70%
MSC: Lewis-Rat, BM-MSC (passage 6 - 8)
Control group (n=6) :PBS
MSC group (n=6) :1×106 cells/body
 Fig. 2  Hepatectomy (70 %) with the I/R injury model in the rat . 
After 40 min of warm ischemia, 70 % hepatectomy was performed, followed by injection of MSCs 
via the portal vein 
 
Mesenchymal Stems Cells for Liver Surgery
286
 Mesenchymal Stem Cells for Pig Ischemia/Reperfusion Injury 
 Pig Ischemia Reperfusion Model 
 Following rat hepatectomy experiments, a preclinical pig model was introduced 
(Fig.  3 ). In our model, long warm ischemia of up to 90 min is simulated for 
Pringle’s procedure during hepatectomy or ischemia/reperfusion injury during 
liver transplantation. Inﬂ ow occlusion, such as Pringle’s occlusion for a long 
period, causes mesenteric congestion, which affects the outcome and can some-
times be lethal. Therefore, a portacaval shunt between the splenic vein and the 
internal jugular vein was placed during inﬂ ow occlusion. The clamp was place at 
the hepatoduodenal ligament for 90 min with intensive monitoring for vital signs. 
After the declamp, MSCs (1.0 × 10 7 /kg) were injected in the MSC group. An initial 
problem with the MSC injection was probable hepatic embolism. Injection of the 
MSCs just after collection from the plates led to severe aggregation of cells, 
 followed by embolus formation. Accordingly, we modiﬁ ed our protocol by immersing 
the MSCs in an ET-Kyoto solution so that the cells would not aggregate. Thereafter, 
Warm ischemia and reperfusion model (pig)
Warm ischemic time :90 min
MSC group (n=3) : AT-MSC    2.3±0.2×108  /body  （1.0±0.1×107 /kg）  via portal vein
Control group (n=3) : saline
 Fig. 3  Warm ischemia and reperfusion model in the pig . 
After 90 min of warm ischemia using Pringle’s procedure, MSCs were injected via the portal vein. 
During Pringle’s procedure, a portacaval shunt was placed in order to avoid mesenteric 
congestion 
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no lethal complication was encountered. After the procedure, the pig was moni-
tored for survival and daily laboratory examinations including AST, ALT, LDH, 
and portal venous pressure.
 Outcome After MSC Injection (Fig.  4 ) 
 All pigs in the MSC group ( n = 5) and control group ( n = 5) survived during an obser-
vation period for 7 days. In the control group, AST, ALT, and LDH peaked several 
hours after the operation and returned to normal in 3 days. However, this increase in 
laboratory parameters was not observed in the MSC group. In terms of adverse 
effects, portal venous pressure (PVP) was kept stable without an increase through-
out the course, in both the MSC group and the control group. Therefore, the modi-
ﬁ ed method for cell preparation is effective to avoid cell aggregation and leads to 
safe application of this method in the clinical setting. As we see from the laboratory 
results, the protective effect of MSCs is suggested in prolonged warm ischemia dur-
ing surgery. This may lead to wider indications in liver surgery and transplantation. 
 Fig. 4  Liver enzymes and PVP in the I/R model in the pig . 
In the pig warm ischemia model, AST, ALT, and LDH were well controlled by MSC administra-
tion. In spite of the MSC administration, portal pressure was maintained without a signiﬁ cant 
increase 
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 Mesenchymal Stem Cells for Rat Whole Liver Transplantation 
with a Long Preservation Period 
 Rat Liver Transplantation Model 
 In the previous section, we showed that MSCs provide a protective effect against 
hepatic ischemia- reperfusion injury and stimulate liver regeneration in rat hepatec-
tomy. We further evaluated the effect of MSCs on liver transplantation after pro-
longed cold preservation by using a rat liver transplantation model. Adipose 
tissue–derived MSCs from luciferase-transgenic Lewis (Luc-Tg LEW) rats were 
cultured and preserved in ET-Kyoto solution before use. Male Lewis rats were used 
as transplantation donors and recipients. The rats were randomly assigned to two 
groups: an MSC group and a control group. The liver grafts were retrieved and pre-
served in UW solution at 4 °C for 24 h. After preservation, 1 × 10 5 of MSCs in 
0.2 ml of ET-Kyoto solution were transfused via the portal vein of the graft in the 
MSC group, and ET-Kyoto solution only was transfused in the control group. Then 
the liver graft was orthotopically transplanted into a recipient rat by the cuff tech-
nique of Kamada and Calne, with minor modiﬁ cation. Both the superior and infe-
rior hepatic vena cava were anastomosed by a running suture. The portal vein was 
connected by a polyethylene cuff and the bile duct by a stent. The hepatic artery was 
reconstructed by the sleeve method. The survival of the recipient rats was evaluated 
for 7 days after transplantation. 
 Outcome After MSCs Injection 
 The anhepatic times were 15.5 ± 0.7 min in the MSC group and 15.4 ± 1.3 min in the 
control group. The inferior vena cava clamping times were 27.6 ± 1.2 min and 
27.1 ± 1.7 min, respectively. Both parameters did not differ signiﬁ cantly between 
the groups. Liver enzymes were better in the MSC group. In the control group, 
prominent necrosis and ballooning of cells in the adjacent area were observed, 
whereas the ﬁ ndings were almost normal in the MSC group (Fig.  5 ). In the MSC 
group, DLK/OV6 double positive cells were observed, whereas positive cells were 
minimal in the control group. These data support the positive effect of MSCs in 
ameliorating ischemia/reperfusion injury. The regenerative effect of MSCs was 
shown as well. The 7-day survival was signiﬁ cantly better in the MSC group than in 
the control group (7/8 vs. 3/8; Fisher’s exact test,  p < 0.05) (Fig.  6 ). Portal transfu-
sion of the MSCs ameliorated the injury of the liver graft after prolonged cold pres-
ervation and transplantation.
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 Experimental Models for Clinical Application 
 Reduced Liver Transplantation (Rat) as a Model for Living- 
Donor Liver Transplantation 
 During the donor operation, the right lobe (RL) of the liver was selected as the graft 
for the 20 % PLTx group, while the superior right lobe (SRL) was selected for the 
15 % PLTx group, on the basis of the rat liver anatomy. Liver grafts were preserved 
in ice-cold HTK solution before implantation for 180 min. The SHVC was sewn 
with an 8-0 Prolene continuous suture, and the portal vein was anastomosed using a 
cuff technique. After conﬁ rming reﬂ ow, the infrahepatic vena cava (IHVC) was 
anastomosed using an 8-0 nylon continuous suture. The hepatic artery was 
connected using a sleeve technique, and the bile duct was reconstructed over an 
 Fig. 5  Histology in liver transplantation using the long-preservation model in the rat . 
An almost normal structure with minimal necrosis was maintained in the MSC group, whereas 
signiﬁ cant necrosis and hepatocyte ballooning in the adjacent area were observed in the control 
group 
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intraluminal stent. With this model, 7-day survival was 100 % with the 20 % graft 
and 17 % with the 15 % graft. Experiments assessing the efﬁ cacy of MSCs are 
under evaluation. 
 Partial Liver Transplantation (Pig) as a Model for Living-Donor 
Liver Transplantation 
 For this preclinical study, the Clawn miniature pig was used for the partial liver 
transplantation model [ 6 ]. The porcine liver consists of four lobes. The right lateral 
lobe (RLL) accounts for 30 % of the whole liver. The structure of the porta hepatis 
was carefully dissected and cut in order to resect the lobes other than the 
RLL. Seventy percent of the liver was resected in the donor, not on the back table, 
to conﬁ rm hemostasis. Then the graft was preserved in the preservation solution for 
3–24 h, followed by implantation into the recipient. In the recipient, prior to total 
hepatectomy, a portacaval shunt was placed to avoid mesenteric congestion. The 
inferior vena cava (suprahepatic and infrahepatic), portal vein, hepatic artery, and 
bile duct were sewn (Fig.  7 ).
 Fig. 6  Survival after liver transplantation in the rat . 
After 24-h preservation, only 38 % (3/8) achieved long-term survival. In contrast, with administra-
tion of MSCs, 88 % (7/8) survived at 7 days after transplantation 
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 Future Perspectives 
 Source for MSCs 
 MSC have been isolated from almost every type of tissue stroma, such as the bone 
marrow, adipose tissue, umbilical cord blood, placenta, kidney, liver, heart, and 
spleen. There are many reports on the positive immunomodulatory effect or regen-
erative effect of MSCs of bone marrow origin. However, retrieval of bone marrow 
from healthy volunteers or patients seems invasive. On the other hand, Banas et al. 
reported a stronger effect of adipose tissue–derived MSCs compared with 
BM-MSCs. Moreover, subcutaneous adipose tissue can be safely retrieved under 
local anesthesia or during a major operation. We have been focusing on utilizing 
MSCs from adipose tissue. The remaining problem is from whom and when adipose 
tissue can be retrieved. Potential donors are the patient him- or herself, the donor of 
the organ in transplantation, or a third party. One of the advantages of MSCs com-
pared with other cell sources is that MSCs express less HLA, leading to less rejec-
tion. Moreover, the regenerative or immunomodulatory effects are expected only in 
the short term, not in the long term. For use in cancer patients, we propose use of the 
patient’s own MSCs without immunosuppression. On the other hand, cells from all 
1. PC shunt with Anthron tube
2. Total hepatectomy
3. Put-in of the graft
4. Anastomosis of SHIVC
5. Anastomosis of IHIVC /       
re-perfusion
6. Withdraw PC shunt
7. Anastomosis of portal        
vein / reflow
8. Anastomosis of hepatic 
artery
9. Anastomosis of bile duct






 Fig. 7  Recipient operation with a reduced graft in the pig . 
In order to avoid mesenteric congestion, a portacaval shunt was placed prior to total hepatectomy. 
Following total hepatectomy, implantation of the graft was done with multiple anastomoses 
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three sources can be utilized in transplant recipients under immunosuppression. For 
an elective cancer operation, the patient’s own MSCs can be retrieved and cultured 
for several weeks. However, stocked cells from a third party can be used for organ 
transplantation performed on an emergency basis [ 7 ,  8 ]. 
 Complications 
 The most severe complication we have encountered is embolus formation due to 
cell aggregation. However, with the modiﬁ cation using ET-Kyoto solution, we can 
keep cells in a suspended form for several hours, which secures safe administration 
of the MSCs. ET-Kyoto solution is commercially available, and its safety is estab-
lished. Potential transformation of MSCs into malignant cells can be problematic; 
however, the lifespan of the cells is limited, according to our study, and they can be 
eliminated within 2 weeks. Mild rejection will help to eliminate cells after a certain 
period as well. 
 Conclusion 
 Thanks to the support of the Uehara Memorial Foundation, we have been able to 
show the positive effect of MSCs with liver surgery. Cell damage during ischemia 
reperfusion injury is ameliorated, and liver regeneration after hepatectomy is 
enhanced by use of intravenous or intraportal MSCs. These positive effects have 
been shown both in vitro and in vivo including in a preclinical pig model. 
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